General
Preferred name
IOTHALAMIC ACID
Synonyms
iotalamic acid ()
IOTHALAMIC ACID I-125 ()
IOTHALAMATE SODIUM ()
DIATRIZOATE SODIUM I 125 ()
IOTHALAMATE MEGLUMINE ()
IOTHALAMATE SODIUM I 131 ()
IOTHALAMATE SODIUM I 125 ()
MI-216 ()
Iothalamate ()
NSC-759891 ()
Angio-Conray ()
Conray 400 ()
Sodium Iothalamate ()
Iothalamic acid sodium salt ()
Iotalamate sodium ()
Sodium Iotalamate Injection ()
Sodium iotalamate ()
Conray ()
Conray 325 ()
Cysto-Conray Ii ()
Meglumine iothalamate ()
Conray 30 ()
Conray 43 ()
Meglumine iotalamate ()
Meglumine Iotalamate Injection ()
Iotalamate meglumine ()
Iothalamate sodium i-125 ()
Iothalamate sodium, i-125 ()
Sodium Iotalamate (125I) ()
Iodine (125i) sodium iotalamate ()
Sodium iotalamate (125 i) ()
Glofil-125 ()
Sodium iothalamate (125i) ()
Iothalamate sodium i125 ()
Diatrizoate sodium i-125 ()
Iodine (131i) sodium iotalamate ()
Iothalamate sodium i-131 ()
Sodium iotalamate (131 i) ()
Conray i 131 ()
Sodium radioiotalamate (131i) ()
Sodium iotalamate (131i) ()
Glofil-131 ()
P&D ID
PD000856
CAS
2276-90-6
13087-53-1
15845-98-4
1225-20-3
Tags
available
drug candidate
drug
Approved by
FDA
First approval
1962
1963
Drug Status
approved
Max Phase
Phase 4
Drug indication
Diagnostic Aid (radiopaque medium)
Radioactive Agent
Diagnostic Aid (radiopaque medium),Radioactive Agent
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
INDICATION Conray is indicated for use in excretory urography, cerebral angiography, peripheral arteriography, venography, arthrography, direct cholangiography, endoscopic retrograde cholangiopancreatography, contrast enhancement of computed tomographic brain images, cranial computerized angiotomography, intravenous digital subtraction angiography and arterial digital subtraction angiography.; Conray may also be used for enhancement of computed tomographic scans performed for detection and evaluation of lesions in the liver, pancreas, kidneys, abdominal aorta, mediastinum, abdominal cavity and retroperitoneal space.
Compound Sets
11
ChEMBL Approved Drugs
CHEMBL1201300
CHEMBL2106318
CHEMBL1201125
CHEMBL1097620
ChEMBL Drugs
CHEMBL1201300
CHEMBL2106318
CHEMBL1201125
CHEMBL1097620
CHEMBL1201123
CHEMBL2104998
Drug Repurposing Hub
DrugBank
DB09133
DrugBank Approved Drugs
DB09133
DrugCentral
1469
DrugCentral Approved Drugs
1469
MedChem Express Bioactive Compound Library
HY-B1053
NCATS Inxight Approved Drugs
16CHD79MIX
2XLB86RCW8
NPC Screening Collection
ReFrame library
External IDs
71
Properties
(calculated by RDKit )
Molecular Weight
613.77
Hydrogen Bond Acceptors
3
Hydrogen Bond Donors
3
Rotatable Bonds
3
Ring Count
1
Aromatic Ring Count
1
cLogP
2.52
TPSA
95.5
Fraction CSP3
0.18
Chiral centers
0.0
Largest ring
6.0
QED
0.46
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
MOA
radiopaque medium
Source data